12:00 AM
 | 
Dec 03, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Ponatinib: Additional Phase I data

Data from a subset of 43 patients with chronic-phase CML in an open-label, dose-escalation, U.S. Phase I trial showed that ponatinib produced a 98% complete hematologic response rate. Additionally, 72% of patients in the subgroup had a major cytogenetic response (MCyR) and 44% had a major molecular response (MMR). In 12 patients with chronic-phase CML with the T315l mutation of BCR-ABL tyrosine kinase, 100% had a complete hematologic response and 92%...

Read the full 331 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >